Aufgrund der verfügbaren Literatur und Daten ist nicht erwiesen, dass eine prophylaktische Thrombozytentransfusion nach myeloablativer Chemotherapie notwendig oder für den Patienten vorteilhaft ist. Die im Verlauf der Jahre immer weiter gesenkten Schwellenwerte zur prophylaktischen Thrombozytentransfusion legten nahe, die Möglichkeit zu überprüfen, auf eine prophylaktische Substitution ganz zu verzichten und nur im Falle relevanter Blutungen zu transfundieren. Mit der hier ausgewerteten Studie liegen erstmals Daten aus einer multizentrischen, prospektiv randomisierten Studie zum Vergleich einer prophylaktischen mit einer therapeutischen Transfusionsstrategie für Thrombozyten nach autologer Stammzelltransplantation vor: es wurde eine prophylaktische Thrombozytentransfusion bei Thrombozytenwerten ≤ 10/nl mit einer neuen Transfusionsstrategie (Substitution nur bei relevanter Blutung oder definierten Risikosituationen) verglichen. Mit der experimentellen, therapeutischen Transfusionsstrategie für Thrombozyten kann eine Reduktion der Thrombozytentransfusionen um ca. 50% im Vergleich zu dem etablierten prophylaktischen Transfusionsregime erreicht werden: bei den hier untersuchten 92 Patienten wurden im experimentellen Arm für 47 Patienten nur 37 Thrombozytenkonzentrate benötigt, für die 45 prophylaktisch behandelten Patienten wurden insgesamt 71 Thrombozytenkonzentrate verbraucht. Die experimentelle therapeutische Transfusionsstrategie für Thrombozyten führte zu keiner statistisch signifikanten Zunahme von Blutungskomplikationen; auch bei der Anzahl der benötigten Erythrozytentransfusionen gab es keine signifikanten Unterschiede; Nebenwirkungen der Transfusionen, Dauer der Thrombopenie und Anzahl der Tage im Krankenhaus waren ebenso nicht signifikant unterschiedlich. Das Risiko, während der Beobachtungszeit (Chemotherapie und autologe Stammzelltransplantation bis zur Regeneration der Thrombozytenwerte), eine Blutung zu erleiden, lag insgesamt bei 14.1%; im experimentellen Arm lag das Risiko bei 19.2%, bei den prophylaktisch substituierten Patienten bei 8.9%; dieser Unterschied war statistisch nicht signifikant, ohnehin traten bei den beobachteten Patienten nur milde, klinisch wenig bedeutsame Blutungen des WHO – Schweregrades < 3 auf, es kam zu keinen blutungsassoziierten Todesfällen Bei klinisch stabilen Patienten und sorgfältiger Überwachung ist ein therapeutisches Transfusionsregime für Thrombozyten nach autologer Stammzelltransplantation praktikabel und sicher anwendbar, die Sicherheit dieses Vorgehens bei Patienten nach autologer Stammzelltransplantation wird mit der vorliegenden randomisierten Studie belegt. Eine therapeutische Thrombozytentransfusionsstrategie ist vermutlich bei einer Vielzahl weiterer hämato-onkologischer Patienten bzw. Krankheitsbilder ausreichend und kann unter signifikanter Einsparung kostbarer Thrombozytenkonzentrate bedrohliche Blutungen ebenso aufhalten oder verhindern wie ein prophylaktisches Regime.

Graft-versus-host disease (GvHD) remains one of the major complications following allogeneic haematopoietic stem cell transplantation (allo-HSCT). GvHD can occur in almost every tissue, with the skin, liver, and intestines being the mainly affected organs. T cells are implicated in initiating GvHD. T cells identify a broad range of antigens and mediate the immune response through receptors on their surfaces (T cell receptors, TCRs). The composition of TCRs within a T cell population defines the TCR repertoire of an individual, and this repertoire represents exposure to self and non-self proteins. Monitoring the changes in the TCR repertoire using TCR sequencing can provide an indication of the dynamics of a T cell population. Monitoring the frequency and specificities of specific TCR clonotypes longitudinally in different conditions and specimens (peripheral blood, GvHD-affected tissue samples) can provide insights into factors modulating immune reactions following allogeneic transplantation and will help to understand the underlying mechanisms mediating GvHD. This review provides insights into current studies of the TCR repertoire in GvHD and potential future clinical implications of TCR sequencing.

Graft-versus-host disease (GvHD) is a frequent, and often life-threatening, complication after an allogeneic, hematopoietic stem cell transplantation (allo-SCT). It can appear in an acute or a chronic form and presents different grades of severity. Particularly, the severe forms of GvHD are often responsible for a change of the curative intent for allo-SCT into a palliative goal of care. For this non-systematic review, we conducted a focused literature search in the MEDLINE database via PubMed to examine whether patients with severe forms of GvHD might have special needs and burdens from a supportive and palliative care perspective. To draw a comprehensive picture of this patient group, we included findings on quality of life (QoL) and physical symptoms and function as well as psychological and spiritual well-being. In most domains, patients with severe forms of GvHD showed greater impairment and a higher symptom burden compared to patients with milder forms of GvHD. However, we could not identify any studies that specifically investigated patients with severe forms of GvHD. Further research in this field is necessary to guarantee the highest standard of care for this very special patient group.

Ein neuartiger Ansatz für die Immunphänotypisierung wird vorgestellt. Die Durchflusszytometrie (FACS) ist die übliche Methode für die Charaketrisierung des Immunsystems. Jedoch ist die Verfügbarkeit von frischem Vollblut, sowie ein schnelle Probenlogistik Vorraussetzung für die Analyse. Als potentialle Alternative werden epigentische qPCR Assays vorgestellt. Für die Quantifizierung von B- und NK-Zellen wurden epigenetische qPCR Systeme etabliert. Anhand eines erweiterten epigenetischen Markerpanels wurde die klinische Anwendung in drei Kohorten getestet: a) 41 Patienten mit primären Immundefizienzen (PID); b) 19 Neugeborene mit und ohne PID und c) 28 Patienten nach einer Stammzelltransplantation (SZT). In Kohorte a) und c) konnte die Äquivalenz der Ergebnisse mit FACS bestätigt werden. Diskrepanzen bei der regulatorischen T-Zell Quantifizierung in einzelnen PID Patienten wurde festgestellt, welche durch Mutationen verursacht wurden, die die Integrität der analysierten Proteine beeinflussen. Zudem konnte die Anwendung der epigentischen Quantifizierung in Trockenblutkarten von Neugeborenen gezeigt werden. Dies würde die Anwendung auch im Neugeborenen-Screening für die Erkennung von PIDs ermöglichen. Für die Anwendung in der SZT konnte gezeigt werden, dass das epigenetische System eine frühe Analyse der Immunrekonstitution ermöglicht, welche eine prädiktive Aussage über das Überleben der Patienten erlaubt. Patienten, welche eine Immunantwort der Lymphozyten gegen eine Virusinfektion bereits am Tag 26 nach Transplantation aufwiesen, hatten eine signifikant höhere Überlebenschance als Patienten ohne Immunantwort. Zusammengefassend zeigen die Daten, dass die epigenetische Systeme für klinische Anwendungen eine zuverlässige Methode darstellt. Die Aussagekraft der Daten ist aufgrund der Studiengröße noch limitiert, und komplizierte klinische Szenarien erschweren die Evaluierung. Deshalb sind weitere Studien erforderlich, um das gezeigte Potenzial zu validieren. / A novel approach for immunophenotyping for clinical applications is presented here. Flow cytometry is currently a common method to characterize the immune system but requiring fresh whole blood and good sample logistics which is not always available. To overcome this limitations, epigenetic qPCR assays are introduced as potential alternative. New epigenetic qPCR systems to quantiy B and NK cells have been established. Using an extended epigenetic marker panel, clinical applications were tested in three patient cohorts: a) 41 patients with different primary immunodeficiencies (PID); b) 19 newborns with and without PID and c) 28 patients after stem cell transplantation (SCT). In cohort a) and c) the equivalence of the epigenetic quantification with flow cytometry was confirmed. However, discrepancies between both methods for regulatory T-cell quantification were found in individual PID patients caused by disease-associated mutations affecting the integrity of the respective protein. Furthermore, the epigenetic quantification using dried blood spots from newborns was demonstrated. This would allow the implementation of epigenetic immunophenotyping in neonatal screening for the detection of congenital immunodeficiencies. For the application in SCT, it was shown that the epigenetic system allows an early analysis of immune reconstitution, which may allow a prediction of the patients' overall survival. Patients who showed an immune response of lymphocytes against viral infections at day 26 after transplantation had a significantly higher survival rate. In summary, the available data show that epigenetic immunophenotyping is a reliable analytical method for various clinical applications. The significance of the data is still limited due to the size of the study and complicated clinical scenarios make the evaluation of individual measurements difficult. Therefore, further extensive investigations are needed to clinically validate the demonstrated potential.

Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in this situation. Induction of a deep response prior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategy following relapse after CAR T-cell therapy has not yet been established. Polatuzumab vedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use in combination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease. Patients: We report two heavily pretreated patients with primary refractory diffuse large Bcell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) respectively who relapsed after therapy with CAR T-cells with both nodal and extranodal manifestations of the disease. After application of three courses of Pola-BR both patients achieved a complete metabolic remission. Both patients underwent alloHSCT from a human leukocyte antigen (HLA)-mismatched donor following conditioning with busulfan and fludarabine and are disease free 362 days and 195 days after alloHSCT respectively. We conclude that Pola-BR can be an effective bridging therapy before alloHSCT of patients relapsing after CAR T-cell therapy. Further studies will be necessary to define the depth and durability of remission of this salvage regimen before alloHSCT.

Sezary Syndrome (SS) is a rare leukemic variant of primary cutaneous T-cell lymphoma. Relapsed or refractory disease is generally considered incurable by conventional therapeutic approaches, although durable responses can be achieved with novel monoclonal antibodies. Allogeneic hematopoietic stem cell transplantation (alloHSCT) may have potential value by inducing graft vs-lymphoma (GvL) effects, but there is currently no consensus regarding the timing of alloHSCT or type of conditioning regimen. Here we present the case of a male patient who achieved a complete remission (CR) of primary refractory SS after non-myeloablative alloHSCT. Patient: Two years prior to HSCT, the patient had been refractory to CHOEP-based chemotherapy, interferon, extracorporeal photopheresis (ECP), and bexarotene. Directly prior to alloHSCT brentuximab-vedotin (BV) was applied resulting in a partial remission of the skin compartment and overall in a stable disease. Prior to HSCT, flow cytometry of the bone marrow and peripheral blood showed an infiltration with T-cells positive for CD5, CD4, low CD3, low CD2 and negative for CD7, CD38, HLA-DR and CD8. The trephine biopsy showed a 7% infiltration of SS cells. The CD4:CD8 ratio in peripheral blood (pb) was massively increased at 76.67, with 63.5% of white blood cells expressing a SS immune phenotype. The conditioning regimen included 30 mg/m2 fludarabine on days -5, -4 and -3 and total body irradiation with 2 Gy on day -1. Immunosuppression consisted of cyclosporine A from day-1 and mycophenolate mofetil from day 0. The patient received 6.55x106 CD34+ cells and 1.11x108 CD3+ cells/kg body weight. Bone marrow evaluation on day 28 still showed persistent SS cells by flow cytometry. After tapering immunosuppression until day 169, the CD4:CD8 ratio in pb normalized. CR was documented on day 169 after alloHSCT and is now ongoing for almost 3 years after alloHSCT. Conclusions: We confirm that an alloHSCT can be a curative option for refractory patients with SS. The achievement of a CR after tapering the immunosuppressive therapy indicates a significant role of the GvL effect. In present treatment algorithms for patients with SS, the timing of an alloHSCT and the intensity of conditioning should be further explored.

Células mesenquimais indiferenciadas humanas foram obtidas por digestão enzimática e centrifugação do produto de lipoaspiração, expandidas in vitro, e implantadas no tecido subcutâneo de camundongos atímicos. No grupo I, cada animal recebeu o implante de uma membrana de 0,25cm2 de ácido glicólico e carbonato de trimetileno semeada com 1 x 106 destas células .No grupo II, cada um recebeu a injeção de 0,2ml de gel de ácido hialurônico reticulado contendo o mesmo número destas células. Com três semanas de implante, células humanas e vasos foram identificados nos dois carreadores. Entretanto, com oito semanas, somente no gel de ácido hialurônico as células humanas e os vasos estavam presentes / Human undifferentiated mesenchymal cells were obtained by enzymatic digestion and centrifugation of the product of liposuction. These cells were expanded, in vitro, and implanted subcutaneously in athymic mice. In group I, each animal received the implant of a 0,25cm2 membrane of glycolic acid and trimethylene carbonate, seeded with 1 x 106 of these cells. In group II, each one received 0,2 ml of cross-linked hyaluronic acid gel containing the same amount of these cells. With three weeks of implantation, human cells and vessels were identified in both carriers. However, with eight weeks of implantation, only in hyaluronic acid gel human cells and vessels were present

Células mesenquimais indiferenciadas humanas foram obtidas por digestão enzimática e centrifugação do produto de lipoaspiração, expandidas in vitro, e implantadas no tecido subcutâneo de camundongos atímicos. No grupo I, cada animal recebeu o implante de uma membrana de 0,25cm2 de ácido glicólico e carbonato de trimetileno semeada com 1 x 106 destas células .No grupo II, cada um recebeu a injeção de 0,2ml de gel de ácido hialurônico reticulado contendo o mesmo número destas células. Com três semanas de implante, células humanas e vasos foram identificados nos dois carreadores. Entretanto, com oito semanas, somente no gel de ácido hialurônico as células humanas e os vasos estavam presentes / Human undifferentiated mesenchymal cells were obtained by enzymatic digestion and centrifugation of the product of liposuction. These cells were expanded, in vitro, and implanted subcutaneously in athymic mice. In group I, each animal received the implant of a 0,25cm2 membrane of glycolic acid and trimethylene carbonate, seeded with 1 x 106 of these cells. In group II, each one received 0,2 ml of cross-linked hyaluronic acid gel containing the same amount of these cells. With three weeks of implantation, human cells and vessels were identified in both carriers. However, with eight weeks of implantation, only in hyaluronic acid gel human cells and vessels were present

La greffe de sang de cordon est de plus en plus utilisée et a permis de traiter avec succès chez l’enfant des déficits immunitaires ainsi que des hémopathies malignes comme les leucémies. Malgré d’importants avantages tels que l’absence de risque pour le donneur ou la plus faible incidence de maladie du greffon contre l’hôte (GvHD), utiliser le sang de cordon comporte certains inconvénients. En effet, une reconstitution immunitaire retardée, des infections opportunistes en plus grand nombre et un risque de rechute sont des complications qui peuvent survenir et engendrer un risque pour le pronostic vital du patient. Par conséquent, de nouvelles stratégies d’immunothérapies doivent être envisagées. Dans le cadre de ce travail, nous nous sommes particulièrement intéressés aux cellules dendritiques plasmacytoides (pDC) dont les fonctions sont importantes pour l’initiation des réponses immunitaires innée et adaptative et particulièrement pour leur capacité à activer les cellules NK. Afin d’élucider le rôle et l’impact de ces cellules dans les greffes de sang de cordon, le nombre et la fonction des pDC et des NK a été suivi longitudinalement chez des patients ayant subi une greffe de sang de cordon comparativement à des patients transplantés avec de la moelle osseuse. Nous avons ainsi démontré que les pDC et les NK apparaissent précocement suite à une greffe de sang de cordon et que ces cellules sont fonctionnelles. Ces résultats mettent donc en lumière que ces cellules pourraient être de bons outils pour l’établissement d’une immunothérapie après greffe de sang de cordon. De plus, la caractérisation fonctionnelle des pDC du greffon de sang de cordon a permis de révéler une plus faible production d’IFN-α par les pDC, comparativement aux pDC de sang d’adulte. Cette différence pourrait jouer un rôle dans la plus faible incidence de GvHD après les greffes de sang de cordon. Dans le but de préciser les mécanismes moléculaires de régulation négative de la production d’IFN-α par les pDC de sang de cordon, nous avons étudié les protéines de la voie de signalisation TLR9-IRF7. L’expression similaire de l’ARN du TLR9, MyD88, IRAK1 et IRF7 contraste avec la plus faible expression des protéines correspondantes. De plus, l’expression des MicroARNs miR-146a et miR-155 est plus élevé dans les pDC de sang de cordon comparativement aux pDC de sang d’adultes. Ensemble, ces données pointent une régulation négative post-transcriptionnelle de la voie TLR9-IRF7 qui pourrait expliquer la plus faible production d’IFN-α des pDC du sang de cordon. L’ensemble des ces travaux suggère que les pDC pourraient représenter une cible de choix dans le développement de nouvelles approches thérapeutiques dans les greffes de sang de cordon. / Umbilical cord blood transplantation has increasingly been used as a source of hematopoietic stem cells to successfully treat immunodeficiencies and malignant diseases such as leukemia in pediatric patients. Despite important advantages, namely lack of risk for the donor and low incidence of GvHD, use of cord blood is associated with several drawbacks. Specifically, delayed immune reconstitution, more opportunistic infections and a relative risk of relapse are complications that may occur and lead to a poor prognosis. Consequently, new immunotherapeutic strategies should be considered. In this study, we were interested in plasmacytoid dendritic cells (pDC), whose functions are important for initiation of innate and adaptive immune responses and, in particular, for their ability to activate natural killer cells (NK). In order to elucidate the role and the impact of these cells in cord blood transplantation, pDC and NK numbers and function have been longitudinally followed in cord blood and bone marrow recipients. We showed that pDC and NK cells appeared early after umbilical cord blood transplantation and that these cells retained functional activity. Thus, these cells may constitute a good tool for immunotherapy in umbilical cord blood transplantation. Moreover, the functional characterization of pDC in cord blood revealed a lower production of IFN-α by cord blood pDC, which may play a role in the lower incidence of GvHD after umbilical cord blood transplantations. In order to determine the molecular mechanism for the negative regulation of IFN-α production by cord blood pDC, we studied the expression of TLR9-IRF7 pathway. The stable expression of TLR9, MyD88, IRAK1 and IRF7 mRNA contrasts with the lower expression of corresponding proteins. Interestingly, expression of microRNA miR-146a and miR-155 is higher in cord blood pDC. Together, these results point to a post-transcriptionnal negative regulation of TLR9-IRF7 pathway which may explain the lower IFN-α production by cord blood pDC. This work reinforces the idea that pDCs constitute a target of choice for developing new therapeutic approaches in cord blood transplantations.

As doenças falciformes (DF) constituem um grupo de doenças hereditárias monogênicas. São doenças extremamente relevantes no contexto de saúde pública no Brasil, portanto diferentes estratégias terapêuticas devem ser avaliadas. As oclusões vasculares afetam praticamente todos os órgãos, inclusive o baço e a medula óssea, porém não existem dados na literatura se estas comprometem também o tecido tímico. Os pacientes apresentam maior suscetibilidade às infecções cujas causas não são ainda totalmente esclarecidas Embora as infecções observadas nos pacientes sejam atribuídas à disfunção esplênica, o quadro inflamatório crônico e possíveis alterações no timo e na medula óssea, também poderiam causar uma disfunção imunológica. O objetivo deste trabalho foi avaliar a neogênese de células T e B e a diversidade do repertório de células T periféricas em pacientes com anemia falciforme (AF) sem tratamento (N = 15), tratados com hidroxiuréia (N = 20) ou transfusão crônica (N = 21) e em pacientes com DF tratados com transplante de células-tronco hematopoéticas (TCTH) alogênico (N = 29). Pacientes sem tratamento apresentaram menores níveis de sjTREC e ?-TREC, e menor taxa de divisão celular intratímica, demonstrando alterações importantes na neogênese das células T. A produção tímica de novas células T naïve foi reestabelecida em um ano pós-transplante, com normalização dos níveis de sjTREC e ?-TREC. O desenvolvimento de doença do enxerto contra o hospedeiro (DECHa) e reativação de citomegalovírus comprometeu a timopoiese nos primeiros seis meses pós-transplante, com diminuição significativa dos níveis de sjTRECs e ?-TRECs. Análises do repertório da cadeia V? dos receptores de células T (TCRs), pelo método TCRBV CDR3 spectratyping, indicaram que os pacientes com AF apresentaram um repertório menos diverso, composto predominantemente de famílias V? com padrão skewed e picos de CDR3 monoclonais, sendo a família V?3 mais frequente. A composição do repertório de células T foi alterada após o transplante, adquirindo um perfil mais policlonal dos picos de CDR3 ao longo do tempo. A família V?22 foi a mais expressa no período pré-transplante e em todos os seguimentos pós-transplante. Os pacientes com DF apresentaram aumento de linfócitos B naive, demonstrado pelos altos níveis de sjKRECs e pela taxa de proliferação homeostática. As análises multivariadas demonstraram que as alterações esplênicas influenciam diretamente os níveis de sjKREC, indicando que a baixa função esplênica leva ao aumento da produção de células B naive pela medula óssea, sugerindo um mecanismo compensatório. Os resultados desse trabalho demonstraram a existência de um desequilíbrio na neogênese de células T e B e consequentemente nesses compartimentos celulares periféricos, que pode conferir aos pacientes com DF uma maior susceptibilidade a infecções. Entre as diferentes modalidades terapêuticas, o TCTH alogênico sobressaiu-se em relação aos tratamentos convencionais, melhorando a neogênese de células T e B a longo prazo. / Sickle Cell Disease (SCD) are a group of monogenic hereditary diseases. These are extremely relevant diseases in the context of public health in Brazil, thus, different therapeutic strategies must be studied. Vascular occlusions affect practically all organs, including the spleen and bone marrow. However, there are no literature data about the impact of vaso-occlusions on the thymic tissue. Patients are more susceptible to infections whose causes are not fully elucidated. Although the infections observed in these patients are assigned to splenic dysfunction, the chronic inflammatory state and possible alterations of the thymus and bone marrow could also lead to immune dysfunction. The goal of this work was to evaluate the neogenesis of T and B cells and the diversity of peripheral T cell repertoire in patients with sickle cell anemia (SCA) without treatment (N = 15), treated with hydroxyurea (N = 20) or chronic transfusions (N = 21) and in patients with SCD treated with hematopoietic stem cell transplantation (N = 29) allogeneic. Patients without treatment had lower levels of sjTREC and ?-TREC, and lower rate of intrathymic cell division, demonstrating important alterations in the neogenesis of T cells. The thymic production of new naïve T cells was reestablished at one-year post transplantation, with normalization of sjTREC and ?-TREC levels. The development of graft-versus-host disease (aGVHD) and cytomegalovirus activation compromised thymopoiesis in the first six months post transplantation, with a significant decrease of sjTRECs and ?-TRECs levels. Analysis of the TCR V? chain repertoire by TCRBV CDR3 spectratyping indicate that patients with SCA showed a less diverse repertoire, mainly composed by V? families with a skewed pattern and monoclonal CDR3 peaks, being the V?3 family the most frequent one. The composition of the T-cell repertoire was altered after transplantation, changing over time to more polyclonal profile of the CDR3 peaks. The V?22 family was the more expressed at pre-transplantation and at all follow-up periods. Patients with SCD presented increased numbers of naive B cells, demonstrated by higher levels of sjKRECs and homeostatic proliferation. Multivariate analysis demonstrated that splenic function directly influenced sjKREC levels, indicating that compromised splenic function leads to increase of naive B cell output by the bone marrow, suggesting a compensatory mechanism. The results of this study showed the existence of an imbalanced T and B cell neogenesis and, consequently on these peripheral cell compartments, which may confer to patients with SCD an increased susceptibility to infections. Among different therapeutic modalities, allogeneic HSCT stood out in relation to the conventional treatments, improving long-term T and B cell neogenesis.